STAT3/5 hyperactivation in CTCL was suggested to contribute to disease progression (Eriksen et al, 2001; Netchiporouk et al, 2014). This evidence concerns the gene STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma.